Study investigator, Dr. Jeffrey Neul, is featured today on NeurologyLive, discussing trofinetide as a potential treatment for Rett syndrome.
NeurologyLive is a media platform for healthcare professionals treating neurological diseases.Dr. Neul points out that, not only is Lavender the first Phase 3 study that has met primary endpoints in Rett syndrome, but it is also one of the first times a successful phase 3 trial has been completed in any neurodevelopmental disorder.
https://www.neurologylive.com/view/trofinetide-as-an-option-rett-syndrome-treatment
- Forums
- ASX - By Stock
- NEU
- Ann: Rett Syndrome NDA accepted for Priority Review by FDA
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-20
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B |
Open | High | Low | Value | Volume |
$20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1024 | $20.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.53 | 285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10 | 20.100 |
1 | 480 | 20.080 |
3 | 174 | 20.000 |
1 | 150 | 19.980 |
1 | 434 | 19.940 |
Price($) | Vol. | No. |
---|---|---|
20.570 | 295 | 1 |
20.600 | 4094 | 1 |
20.610 | 13 | 1 |
20.650 | 2488 | 1 |
20.700 | 252 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |